Acute hemodynamic effects of hydralazine in dogs with chronic mitral regurgitation
- PMID: 4030462
Acute hemodynamic effects of hydralazine in dogs with chronic mitral regurgitation
Abstract
The hemodynamic response to hydralazine administration was evaluated in 6 conscious small dogs with chronic mitral regurgitation. All dogs underwent invasive and noninvasive hemodynamic monitoring before and after hydralazine administration. Cardiac output and pulmonary capillary wedge pressure were measured with a Swan-Ganz thermodilution catheter. Systemic arterial blood pressure (AP) was measured directly by inserting a needle into the femoral artery. Standard M-mode echocardiograms and thoracic radiographs were obtained. Other hemodynamic variables were calculated. Base-line hemodynamic variables were altered severely in all dogs. Hydralazine decreased mean arterial blood pressure from 104 +/- 18 (mean +/- SD) to 78 +/- 12 mm of Hg (P less than 0.005), total systemic resistance index from 2,946 +/- 625 to 1,261 +/- 420 dynes-s-cm-5m2 (P less than 0.005), and pulmonary capillary wedge pressure from 40 +/- 5 to 26 +/- 3 mm of Hg, (P less than 0.005). Cardiac index increased from 2.92 +/- 0.72 to 5.36 +/- 1.67 L/min/m2 of body surface area (P less than 0.005). Mixed venous oxygen tension (PvO2) increased from 28.4 +/- 4.3 to 41.2 +/- 5.2 mm of Hg (P less than 0.001). Pulmonary edema resolved, as determined on thoracic radiographs. Mixed venous oxygen tension correlated well with the cardiac index (r = 0.92; P less than 0.001). It was concluded that hydralazine administration caused a small decrease in end diastolic diameter (4.8 +/- 0.9 to 4.5 +/- 0.8 cm, P less than 0.05) and end systolic diameter (2.6 +/- 0.8 to 2.3 +/- 0.7 cm, P less than 0.05). Fractional shortening and heart rate did not change.(ABSTRACT TRUNCATED AT 250 WORDS)
Similar articles
-
Acute effect of hydralazine administration on pulmonary artery hemodynamics in dogs with chronic heartworm disease.Am J Vet Res. 1994 Feb;55(2):262-9. Am J Vet Res. 1994. PMID: 8172418
-
Hydralazine pharmacodynamics in the dog.Am J Vet Res. 1983 Aug;44(8):1501-5. Am J Vet Res. 1983. PMID: 6625299
-
Effects of hydralazine on cardiopulmonary function in canine low-pressure pulmonary edema.Anesthesiology. 1983 Sep;59(3):187-90. Anesthesiology. 1983. PMID: 6881582
-
Hydralazine in heart failure.Herz. 1983 Aug;8(4):187-98. Herz. 1983. PMID: 6413340 Review.
-
Acute lung injury. Hemodynamic monitoring with the pulmonary artery catheter.Crit Care Clin. 1986 Jul;2(3):551-72. Crit Care Clin. 1986. PMID: 3331562 Review.
Cited by
-
Hydralazine pharmacokinetics and interaction with food: an evaluation of the dog as an animal model.Pharm Res. 1990 Mar;7(3):274-9. doi: 10.1023/a:1015830330231. Pharm Res. 1990. PMID: 2339102
-
Current concepts in vasodilator therapy for advanced or refractory congestive heart failure.Can Vet J. 1988 Apr;29(4):354-61. Can Vet J. 1988. PMID: 17423025 Free PMC article.
-
Survival and echocardiographic data in dogs with congestive heart failure caused by mitral valve disease and treated by multiple drugs: a retrospective study of 21 cases.Can Vet J. 2011 Nov;52(11):1219-25. Can Vet J. 2011. PMID: 22547843 Free PMC article.
-
Evaluation of presentation, treatment and outcome in hypertensive emergency in dogs and cats: 15 cases (2003-2019).J Small Anim Pract. 2022 Oct;63(10):784-791. doi: 10.1111/jsap.13530. Epub 2022 Jul 10. J Small Anim Pract. 2022. PMID: 35811381 Free PMC article.
-
Management of Chronic Congestive Heart Failure Caused by Myxomatous Mitral Valve Disease in Dogs: A Narrative Review from 1970 to 2020.Animals (Basel). 2022 Jan 16;12(2):209. doi: 10.3390/ani12020209. Animals (Basel). 2022. PMID: 35049831 Free PMC article. Review.